FDA Again Rejects J&J, Bayer Blood Thinner Expansion
The U.S. Food and Drug Administration refused for the third time to expand use of Johnson & Johnson and Bayer AG's blood thinner Xarelto to include treatment of acute coronary syndrome,...To view the full article, register now.
Already a subscriber? Click here to view full article